| Literature DB >> 28958624 |
Arun K Ghosh1, W Sean Fyvie2, Margherita Brindisi2, Melinda Steffey2, Johnson Agniswamy3, Yuan-Fang Wang3, Manabu Aoki4, Masayuki Amano4, Irene T Weber3, Hiroaki Mitsuya5.
Abstract
Design, synthesis, and evaluation of a new class of HIV-1 protease inhibitors containing diverse flexible macrocyclic P1'-P2' tethers are reported. Inhibitor 5a with a pyrrolidinone-derived macrocycle exhibited favorable enzyme inhibitory and antiviral activity (Ki=13.2nM, IC50=22nM). Further incorporation of heteroatoms in the macrocyclic skeleton provided macrocyclic inhibitors 5m and 5o. These compounds showed excellent HIV-1 protease inhibitory (Ki=62pM and 14pM, respectively) and antiviral activity (IC50=5.3nM and 2.0nM, respectively). Inhibitor 5o also remained highly potent against a DRV-resistant HIV-1 variant.Entities:
Keywords: Drug resistance; HIV protease; Macrocyclic inhibitors; P1′-P2′ ligands; Structure-based design
Mesh:
Substances:
Year: 2017 PMID: 28958624 PMCID: PMC5647257 DOI: 10.1016/j.bmcl.2017.09.003
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823